Kayne Anderson Rudnick Investment Management LLC Has $195.56 Million Holdings in West Pharmaceutical Services, Inc. (NYSE:WST)

Kayne Anderson Rudnick Investment Management LLC increased its position in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 6.8% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 593,692 shares of the medical instruments supplier’s stock after buying an additional 37,702 shares during the period. Kayne Anderson Rudnick Investment Management LLC owned 0.82% of West Pharmaceutical Services worth $195,556,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Fidelis Capital Partners LLC acquired a new stake in shares of West Pharmaceutical Services in the first quarter valued at approximately $27,000. Crewe Advisors LLC boosted its position in West Pharmaceutical Services by 322.7% during the second quarter. Crewe Advisors LLC now owns 93 shares of the medical instruments supplier’s stock worth $31,000 after purchasing an additional 71 shares during the period. Quarry LP increased its holdings in shares of West Pharmaceutical Services by 155.3% in the fourth quarter. Quarry LP now owns 97 shares of the medical instruments supplier’s stock valued at $34,000 after purchasing an additional 59 shares during the last quarter. Hazlett Burt & Watson Inc. bought a new position in shares of West Pharmaceutical Services in the first quarter valued at about $40,000. Finally, Northwest Investment Counselors LLC acquired a new stake in shares of West Pharmaceutical Services during the 1st quarter worth about $40,000. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Price Performance

Shares of NYSE WST opened at $308.15 on Friday. The firm has a market cap of $22.45 billion, a P/E ratio of 40.65, a price-to-earnings-growth ratio of 10.58 and a beta of 1.01. The business’s 50 day moving average is $303.37 and its 200-day moving average is $337.42. The company has a current ratio of 2.34, a quick ratio of 1.68 and a debt-to-equity ratio of 0.03. West Pharmaceutical Services, Inc. has a 1-year low of $265.00 and a 1-year high of $413.70.

West Pharmaceutical Services (NYSE:WST) last released its quarterly earnings results on Thursday, July 25th. The medical instruments supplier reported $1.52 EPS for the quarter, missing the consensus estimate of $1.74 by ($0.22). West Pharmaceutical Services had a net margin of 18.25% and a return on equity of 19.17%. The business had revenue of $702.10 million during the quarter, compared to analyst estimates of $729.36 million. During the same quarter last year, the company posted $2.11 earnings per share. The company’s revenue was down 6.9% on a year-over-year basis. Equities research analysts predict that West Pharmaceutical Services, Inc. will post 6.42 earnings per share for the current year.

Insider Activity

In other West Pharmaceutical Services news, VP Charles Witherspoon sold 1,029 shares of the stock in a transaction dated Monday, August 19th. The shares were sold at an average price of $300.00, for a total transaction of $308,700.00. Following the sale, the vice president now directly owns 1,478 shares in the company, valued at $443,400. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 0.53% of the company’s stock.

West Pharmaceutical Services Profile

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.